Eri Sugiyama
About
Eri Sugiyama is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Eri Sugiyama has authored 21 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Eri Sugiyama's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Eri Sugiyama is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Eri Sugiyama collaborates with scholars based in Japan, United States and United Kingdom. Eri Sugiyama's co-authors include Kōichi Goto, Genichiro Ishii, Shingo Matsumoto, Masahiro Tsuboi, Shigeki Umemura, Yosuke Togashi, Hiroyoshi Nishikawa, Kenta Tane, Meinoshin Okumura and Yasuko Tada and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Annals of Oncology.
In The Last Decade
Eri Sugiyama
19 papers receiving 500 citations
Peers
Eri Sugiyama
Caterina Aversa Italy
Sandeep Rajput United States
Fangfang Li China
Marjan Taherian Iran
Batool Shannan Germany
Giovanni Brigliadori Italy
Sven de Mey Belgium
Marilù Fanelli Italy
David Xu United States
Sharareh Siamakpour‐Reihani United States
Citations per year, relative to Eri Sugiyama Eri Sugiyama (= 1×)
peers
Caterina Aversa
Countries citing papers authored by Eri Sugiyama
Since
Specialization
Citations
This map shows the geographic impact of Eri Sugiyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eri Sugiyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eri Sugiyama more than expected).
Fields of papers citing papers by Eri Sugiyama
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eri Sugiyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eri Sugiyama. The network helps show where Eri Sugiyama may publish in the future.
Co-authorship network of co-authors of Eri Sugiyama
This figure shows the co-authorship network connecting the top 25 collaborators of Eri Sugiyama. A scholar is included among the top collaborators of Eri Sugiyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eri Sugiyama. Eri Sugiyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Taki, Tetsuro, Naoya Sakamoto, Shingo Sakashita, et al.. (2024). NET osis in pulmonary pleomorphic carcinoma. Cancer Science. 116(2). 524–532.
2.
Izumi, Hiroki, Tetsuro Taki, Tetsuya Sakai, et al.. (2024). Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma. JTO Clinical and Research Reports. 6(3). 100779–100779.
3.
Kitagawa, Shingo, Yoshitaka Zenke, Kiyotaka Yoh, et al.. (2023). 236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD. Annals of Oncology. 34. S275–S276.
4.
Yoh, Kiyotaka, Yoshitaka Zenke, Shingo Kitagawa, et al.. (2023). 1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S737–S737.
5.
Zenke, Yoshitaka, Kiyotaka Yoh, Shingo Kitagawa, et al.. (2023). 1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S740–S741.
6.
Sakai, Tetsuya, Shingo Matsumoto, Yuji Shibata, et al.. (2023). Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia). Journal of Thoracic Oncology. 18(11). 1538–1549.
7.
Udagawa, Hibiki, Eri Sugiyama, Toshiyuki Harada, et al.. (2021). Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR). Translational Lung Cancer Research. 10(7). 3059–3070.
8.
Sugiyama, Eri, Yosuke Togashi, Yoshiko Takeuchi, et al.. (2020). Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer. Science Immunology. 5(43).
9.
Kirita, Keisuke, Eri Sugiyama, Yosuke Togashi, et al.. (2019). Clinical utility of precision immunoprofiling and monitoring of the tumour microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: Results from a phase II study for biomarker analysis (EPOC1702). Annals of Oncology. 30. v507–v507.
10.
Koyama, Ryo, Hibiki Udagawa, Eri Sugiyama, et al.. (2018). Randomized phase II study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small cell lung cancer (CLEAR study). Annals of Oncology. 29. viii518–viii518.
11.
Fukuoka, Shota, Daisuke Motooka, Yosuke Togashi, et al.. (2018). Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.. Journal of Clinical Oncology. 36(15_suppl). 3011–3011.
12.
Atagi, Shinji, Hibiki Udagawa, Eri Sugiyama, et al.. (2017). P1.03-027 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study). Journal of Thoracic Oncology. 12(11). S1961–S1961.
13.
Zenke, Yoshitaka, Shigeki Umemura, Eri Sugiyama, et al.. (2016). Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 99. 1–3.
14.
Makinoshima, Hideki, Masahiro Takita, Koichi Saruwatari, et al.. (2015). Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma. Journal of Biological Chemistry. 290(28). 17495–17504.
15.
Sugiyama, Eri, Shigeki Umemura, Shogo Nomura, et al.. (2015). Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 90(2). 307–313.
16.
Sugiyama, Eri, Kōichi Goto, Genichiro Ishii, et al.. (2012). Higher incidence of EGFR exon 19 deletion in younger (age 40 or younger) patients with adenocarcinoma of the lung.. Journal of Clinical Oncology. 30(15_suppl). 7044–7044.
17.
Tozuka, Yuichi, Eri Sugiyama, & Hirofumi Takeuchi. (2009). Release profile of insulin entrapped on mesoporous materials by freeze–thaw method. International Journal of Pharmaceutics. 386(1-2). 172–177.
18.
Ueno, Hironori, Takuji Okusaka, Nagahiro Saijo, et al.. (2007). 508 POSTER Association of genetic polymorphisms with survival in Japanese pancreatic cancer patients treated with gemcitabine. European Journal of Cancer Supplements. 5(4). 92–92.
19.
Eto, Masashi, et al.. (1998). Phencyclone Diels-Alder adducts as a new crystalline host. Role of CH···π and CH···O interactions. Tetrahedron Letters. 39(52). 9751–9754.
20.
Maruyama, Keiko, Y. Sugita, Yoko Takada, et al.. (1991). MCI-9042: High affinity for serotonergic receptors as assessed by radioligand binding assay.. Journal of Pharmacobio-Dynamics. 14(4). 177–181.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by Sandeep Rajput Breakdown of academic impact, for papers by Fangfang Li Breakdown of academic impact, for papers by Marjan Taherian Breakdown of academic impact, for papers by Batool Shannan Breakdown of academic impact, for papers by Giovanni Brigliadori Breakdown of academic impact, for papers by Sven de Mey Breakdown of academic impact, for papers by Marilù Fanelli Breakdown of academic impact, for papers by David Xu Breakdown of academic impact, for papers by Sharareh Siamakpour‐Reihani